Drugs / NS-018
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01423851 | Jun 2011 → Apr 2020 | myelofibrosis, primary myelofibrosis | NS Pharma, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04854096 | Jan 2023 → May 2024 | myelofibrosis, primary myelofibrosis | NS Pharma, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-12-05 | Nippon Shinyaku Co., Ltd. | Results 第58回米国血液学会でのNS-018臨床データ発表のお知らせ nippon-shinyaku.co.jp ↗
その結果、26例中16例（62％）について、QOLの改善や生存に関連すると報告されている10%以上の脾容積縮小を達成しました。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-08-08 | Nippon Shinyaku Co., Ltd. | 海外で開発中の骨髄線維症治療剤「NS-018」欧州におけるオーファンドラッグ指定のお知らせ nippon-shinyaku.co.jp ↗ |
| 2022-12-20 | Nippon Shinyaku Co., Ltd. | 海外で開発中の骨髄線維症治療剤「NS-018」米国におけるオーファンドラッグ指定のお知らせ nippon-shinyaku.co.jp ↗ |
| 2016-12-05 | Nippon Shinyaku Co., Ltd. | 第58回米国血液学会でのNS-018臨床データ発表のお知らせ nippon-shinyaku.co.jp ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NS-018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04854096 ↗ |
| Known as | Ilginatinib | ChEMBL registry synonym — accepted as the source's own label CHEMBL4303389 ↗ |
| Action | Inhibit | “NS-018 is a Janus-activated kinase 2 (JAK2)-selective inhibitor” PMID 27479177 ↗ Aug 2016 |
| Modality | Small molecule | — CHEMBL4303389 ↗ |
| Route | Oral | “patients with myelofibrosis received oral NS-018 in continuous 28-day cycles” PMID 27479177 ↗ Aug 2016 |
| Target | JAK2 | “NS-018 is a Janus-activated kinase 2 (JAK2)-selective inhibitor” PMID 27479177 ↗ Aug 2016 |